SCHEMBL3055009

SCHEMBL3055009

O=C(CNC(=O)c1ccc(S(=O)(=O)N(Oc2ccc(Cl)cc2Cl)c2ccccc2)cc1)NCCCN1CCOCC1

nearest known ligand 0.54

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.51
SMN1; SMN2 Q16637 3/20 0.51
TDP1 Q9NUW8 1/20 0.51
CA12 O43570 1/20 0.49
CA9 Q16790 1/20 0.49
GAA P10253 2/20 0.48
RXFP1 Q9HBX9 1/20 0.47
KMT2A Q03164 2/20 0.46
KDM4E B2RXH2 1/20 0.46
LMNA P02545 1/20 0.45
CYP2D6 P10635 1/20 0.44
CYP2C9 P11712 1/20 0.44
MEN1 O00255 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3044072 0.93 F10 (0.46) ALDH1A1SMN1; SMN2TDP1CA12CA9
SCHEMBL3054196 0.91 CCR2 (0.45) ALDH1A1SMN1; SMN2CA12CA9KMT2A
SCHEMBL3281600 0.89 ALDH1A1 (0.45) ALDH1A1SMN1; SMN2TDP1CA12CA9
SCHEMBL3148182 0.89 F10 (0.51) ALDH1A1SMN1; SMN2TDP1CA12CA9
SCHEMBL15103873 0.88 ALDH1A1 (0.43) ALDH1A1SMN1; SMN2TDP1CA12CA9
SCHEMBL3274385 0.88 ALDH1A1 (0.43) ALDH1A1SMN1; SMN2TDP1CA12CA9
SCHEMBL15103806 0.85 KMT2A (0.45) ALDH1A1SMN1; SMN2GAAKMT2AKDM4E
SCHEMBL3053490 0.84 KMT2A (0.51) ALDH1A1SMN1; SMN2KMT2AKDM4ELMNA
SCHEMBL3040685 0.84 CACNA1G (0.45) ALDH1A1GAAKDM4ELMNA
SCHEMBL3275589 0.84 PSEN1 (0.43) SMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120295910-A1 New Phenylsulfamoyl Benzamide Derivatives as Bradykinin Antagonists BEKE GYULA (HU) 2012-11-22 US claimed
US-20100105686-A1 PHENYLSULFAMOYL BENZAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS RICHTER GEDEON NYRT. (HU) 2010-04-29 US claimed
EP-2057116-A1 NEW PHENYLSULFAMOYL BENZAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS Richter Gedeon NYRT (HU) 2009-05-13 EP claimed
WO-2008050167-A1 NEW PHENYLSULFAMOYL BENZAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS RICHTER GEDEON NYRT. (HU) 2008-05-02 WO claimed
EP-2057116-B1 NEW PHENYLSULFAMOYL BENZAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS RICHTER GEDEON NYRT (HU) 2013-02-13 EP disclosed
US-20130029991-A1 New Phenylsulfamoyl Benzamide Derivatives as Bradykinin Antagonists BEKE GYULA (HU) 2013-01-31 US disclosed
US-20120295910-A1 New Phenylsulfamoyl Benzamide Derivatives as Bradykinin Antagonists BEKE GYULA (HU) 2012-11-22 US disclosed
US-20100105686-A1 PHENYLSULFAMOYL BENZAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS RICHTER GEDEON NYRT. (HU) 2010-04-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120295910-A1 New Phenylsulfamoyl Benzamide Derivatives as Bradykinin Antagonists BDKRB1, BDKRB2, HRH4 ALDH1A1 3460/4885SMN1; SMN2 4333/4885TDP1 4167/4885
US-20130029991-A1 New Phenylsulfamoyl Benzamide Derivatives as Bradykinin Antagonists BDKRB1, BDKRB2, HRH4 ALDH1A1 3348/4885SMN1; SMN2 4307/4885TDP1 4198/4885
US-20100105686-A1 PHENYLSULFAMOYL BENZAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS BDKRB1, BDKRB2, HRH1 ALDH1A1 2910/4885SMN1; SMN2 4111/4885TDP1 4005/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.